Objective assessment of lymphatic and blood vascular invasion in lymph node-negative breast carcinoma: findings from a large case series with long-term follow-up

Background: Lymph node involvement is a major independent prognostic factor for survival in patients with malignant melanoma. Sentinel lymph node biopsy (SLNB) detection of microscopic nodal melanoma has been shown to improve both 5-year survival and 5-year disease-free survival. Objective: To determine the rate of metastatic melanoma in SLNB-negative patients at long-term follow-up. Methods: Study subjects include all 152 patients who had a negative SLNB and were followed at the Ottawa Regional Cancer Centre (ORCC) between 1999 and 2004. Patients with a follow-up period less than 6 months, more than 1 primary melanoma, and metastatic melanoma at diagnosis were excluded. Age at diagnosis, sex, Breslow thickness, ulceration, mitoses, regression, Clark level, anatomical location, development of metastatic melanoma, time to detection of metastatic disease, and time to death from melanoma were studied. Results: In this retrospective study at the ORCC, 40 of 140 (28.6%) patients with a single primary melanoma developed metastatic melanoma following negative SLNB at a mean follow-up of 63 months. Conclusion: The rate of metastatic melanoma following negative SLNB at long-term follow-up at the ORCC is higher than the upper limit of rates reported in the literature (6%-24%). The reason for this is multifactorial, and the long follow-up period of 5 years allowed for detection of metastatic disease at a mean of 3.9 years. Long-term prognosis may be guarded in node-negative patients with a primary cutaneous melanoma, and surveillance by a multidisciplinary team is crucial.

Download Full-text

LONG-TERM FOLLOW-UP AFTER SENTINEL LYMPH NODE BIOPSY IN EARLY-STAGE VULVAR CANCER

10.26226/morressier.599bdc7bd462b80296ca1c53 ◽

2017 ◽

Author(s):

Núria Agustí Garcia

Keyword(s):

Lymph Node ◽

Sentinel Lymph Node ◽

Sentinel Lymph Node Biopsy ◽

Vulvar Cancer ◽

Early Stage ◽

Lymph Node Biopsy ◽

Node Biopsy ◽

Long Term Follow Up

Download Full-text

Percutaneous cervical cordotomy for the treatment of cancer pain: A prospective case series of 52 patients with a long‐term follow‐up

Pain Practice ◽

10.1111/papr.12991 ◽

2020 ◽

Author(s):

Paul J. Zomers ◽

George Groeneweg ◽

Sara Baart ◽

Frank J.P. Huygen

Keyword(s):

Cancer Pain ◽

Case Series ◽

Long Term Follow Up ◽

Prospective Case Series

Download Full-text

Long-Term Follow-Up of Denosumab Discontinuers with Multiple Vertebral Fractures in the Real-World: A Case Series

Hormone and Metabolic Research ◽

10.1055/a-1368-4218 ◽

2021 ◽

Author(s):

Liana Tripto-Shkolnik ◽

Yair Liel ◽

Naama Yekutiel ◽

Inbal Goldshtein

Keyword(s):

Real World ◽

Vertebral Fractures ◽

Clinical Laboratory ◽

Case Series ◽

High Risk Group ◽

Imaging Data ◽

Long Term Follow Up ◽

Multiple Vertebral Fractures

AbstractDenosumab discontinuation is associated with rapid reversal of bone turnover suppression and with a considerable increase in fracture risk, including a risk for multiple vertebral fractures (MVF). Long-term follow-up of patients who sustained MVF after denosumab discontinuation has not been reported. This case-series was aimed to provide a long-term follow-up on the management and outcome of denosumab discontinuers who initially presented with multiple vertebral fractures. Denosumab discontinuers were identified from a computerized database of a large healthcare provider. Baseline and follow-up clinical, laboratory, and imaging data were obtained from the computerized database and electronic medical records. The post-denosumab discontinuers MVF patients consisted of 12 women aged 71±12. Osteoporotic fractures were prevalent before denosumab discontinuation in 6 of the patients. The majority received bisphosphonates before denosumab. MVF occurred 134±76 days after denosumab discontinuation. The patients were followed for a median of 36.5 (IQR 28.2, 42.5) months after MVF. Two patients passed-away. Two patients suffered recurrent vertebral fractures. Following MVF, patients were treated inconsistently with denosumab, teriparatide, oral, and intravenous bisphosphonates, in various sequences. Two patients underwent vertebroplasty/kyphoplasty. This long-term follow-up of real-world patients with MVF following denosumab discontinuation reveals that management is inconsistent, and recurrent fractures are not uncommon. It calls for clear management guidelines for patients with MVF after denosumab discontinuation and for special attention to this high-risk group.

Download Full-text

The Role of Pretreatment FDG-PET in Treating Cervical Cancer Patients With Enlarged Pelvic Lymph Node(s) Shown on MRI: A Phase 3 Randomized Trial With Long-Term Follow-Up

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2015.02.027 ◽

2015 ◽

Vol 92 (3) ◽

pp. 577-585 ◽

Cited By ~ 10

Author(s):

Shinn-Yn Lin ◽

Chien-Sheng Tsai ◽

Yu-Chen Chang ◽

Koon-Kwan Ng ◽

Ting-Chang Chang ◽

...

Keyword(s):

Cervical Cancer ◽

Lymph Node ◽

Randomized Trial ◽

Cancer Patients ◽

Fdg Pet ◽

Phase 3 ◽

Long Term Follow Up

Download Full-text

Long-Term Follow-Up after Radiotherapy of Hidradenitis Suppurativa

Dermatology ◽

10.1159/000517252 ◽

2021 ◽

pp. 1-7

Author(s):

Jurr Boer

Keyword(s):

Total Dose ◽

Hidradenitis Suppurativa ◽

Early Stage ◽

Case Reports ◽

Case Series ◽

Postal Survey ◽

Long Term Follow Up ◽

Late Treatment

Background: Patients with hidradenitis suppurativa (HS) are still often disappointed with the current treatments offered and there is a clear demand for more effective options. Since the late 1990s there has been a revival in the use of radiotherapy (RT) for different benign diseases, including HS. During the past 20 years one case series and some scattered case reports have described promising results of RT. Objectives: To evaluate the long-term efficacy of RT in early-stage HS. Methods: A postal survey-based long-term follow-up with simple factual questions of partly retrospective and partly contemporary characteristics was performed. Sixty-four patients (96 axillae), diagnosed with mild to moderate HS were irradiated with a orthovoltage unit with 100 kV, 3 mm Al or 200 kV, 0.5 Cu filtering, respectively. Four to six biweekly fractional doses ranging from 0.75 to 1 Gy up to a total dose of 6 Gy in one series, and in chronic cases followed by four daily fractions of 2 Gy up to a total dose of 14 Gy, were given. Late treatment toxicity and the rate of remission of the disease were evaluated. Results: The overall response rate of the survey was 64.1% with 40.6% (26/64) valid, complete questionnaires. In total, 40 axillae were irradiated in these 26 patients. After a median follow-up of 40 years (range 32–52) complete remission of the lesions occurred in 34 of the 40 sites (85%). None of the 26 patients with 40 irradiated sites reported adverse effects at the time of the survey. Conclusions: RT appears to be an effective treatment for early and mild HS in the majority of patients. In this case series, no side effects were reported after a median follow-up period of 40 years.

Download Full-text